Drug-induced liver injury following the use of tocilizumab or sarilumab in patients with coronavirus disease 2019

BACKGROUNDS: Interleukin-6 (IL-6) blockers including tocilizumab and sarilumab were approved by the U.S. Food and Drug Administration (FDA) in June 2021 for the treatment of patients with moderate to severe COVID-19. The use of sarilumab or tocilizumab in COVID-19 patients has been related to a redu...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Qian, Yin, Xuedong, Tan, Boyu, Wang, Junshi, Chen, Jiayan, Zhao, Bin, Yang, Qiaoling, Li, Zhiling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742033/
https://www.ncbi.nlm.nih.gov/pubmed/36503381
http://dx.doi.org/10.1186/s12879-022-07896-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742033/
https://www.ncbi.nlm.nih.gov/pubmed/36503381
http://dx.doi.org/10.1186/s12879-022-07896-0

Ejemplares similares